# A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

> **NCT01830543** · PHASE3 · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 2124 (actual)

## Conditions studied

- Atrial Fibrillation
- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** rivaroxaban 2.5 mg
- **DRUG:** rivaroxaban 15 mg
- **DRUG:** rivaroxaban 10 mg
- **DRUG:** aspirin (ASA)
- **DRUG:** vitamin K antagonist (VKA)
- **DRUG:** clopidogrel
- **DRUG:** prasugrel
- **DRUG:** ticagrelor

## Key facts

- **NCT ID:** NCT01830543
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-10
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-07-28
- **Target enrollment:** 2124 (ACTUAL)
- **Last updated:** 2017-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830543, "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01830543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*